S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Focus:Use of S303 RBCs in Patients With Acute Anemia
Conditions
Focus:Use of S303 RBCs in Patients With Acute Anemia
Trial Timeline
Apr 1, 2013 → Oct 1, 2014
NCT ID
NCT01716923About S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control is a phase 3 stage product being developed by Cerus for Focus:Use of S303 RBCs in Patients With Acute Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01716923. Target conditions include Focus:Use of S303 RBCs in Patients With Acute Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01716923 | Phase 3 | Completed |
Other Products from Cerus
Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44
INTERCEPT treated plateletsPhase 2
44